These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 33055081)
41. [Management of Rheumatic Diseases during the COVID-19 Pandemic: Beyond Telehealth Services]. Fernandes AL; Silva C; Miranda LC Acta Med Port; 2020 Oct; 33(10):706. PubMed ID: 32840207 [No Abstract] [Full Text] [Related]
42. [Rheumatology and COVID-19]. Dumusc A; Dan D Rev Med Suisse; 2020 Apr; 16(N° 691-2):831-834. PubMed ID: 32348046 [TBL] [Abstract][Full Text] [Related]
43. Addressing the challenges of the SARS-CoV-2 pandemic in patients affected by autoimmune and rheumatic disease. Robinson PC; Kim AHJ Best Pract Res Clin Rheumatol; 2021 Mar; 35(1):101664. PubMed ID: 33610466 [No Abstract] [Full Text] [Related]
44. [Hydroxychloroquine. Cardiology's viewpoint in times of coronavirus pandemic]. Zaidel EJ; Wyss Quintana FS; Sosa Liprandi Á; Mendoza I; Márquez MF; Nuñez E; Barbosa M; Baranchuk A Medicina (B Aires); 2020; 80(3):271-274. PubMed ID: 32442941 [TBL] [Abstract][Full Text] [Related]
45. How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion. Sarzi-Puttini P; Marotto D; Antivalle M; Salaffi F; Atzeni F; Maconi G; Monteleone G; Rizzardini G; Antinori S; Galli M; Ardizzone S Autoimmun Rev; 2020 Jul; 19(7):102574. PubMed ID: 32376399 [TBL] [Abstract][Full Text] [Related]
46. COVID-19 information uptake amongst a rheumatology interested population. Katz SJ; Hall JJ Clin Rheumatol; 2023 May; 42(5):1491-1493. PubMed ID: 36892709 [No Abstract] [Full Text] [Related]
47. Reflections on the COVID-19 Pandemic: Impacts on Clinical Rheumatology Research. Huffman KF; Grimm KF; Allen KD Arthritis Care Res (Hoboken); 2024 Jan; 76(1):15-18. PubMed ID: 37533231 [No Abstract] [Full Text] [Related]
48. Should we be using the Covid-19 outbreak to prompt us to transform our rheumatology service delivery in the technology age? Jethwa H; Abraham S Rheumatology (Oxford); 2020 Jul; 59(7):1469-1471. PubMed ID: 32441754 [No Abstract] [Full Text] [Related]
49. Comorbidities and rheumatological diseases at the time of COVID-19. Response to: 'Rheumatic diseases in intensive care unit patients with COVID-19' by Moiseev Monti S; Montecucco C Ann Rheum Dis; 2021 Feb; 80(2):e17. PubMed ID: 32434818 [No Abstract] [Full Text] [Related]
51. Biological therapies in children with rheumatic diseases during the COVID-19 pandemic: A single-centre experience. Aydın F; Kurt T; Sezer M; Tekgöz N; Ekici Tekin Z; Kanık Yüksek S; Çelikel Acar B Int J Clin Pract; 2021 Jul; 75(7):e14030. PubMed ID: 34233400 [No Abstract] [Full Text] [Related]
52. Response to: 'Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab' by Schulze-Koops Monti S; Montecucco C Ann Rheum Dis; 2021 May; 80(5):e68. PubMed ID: 32591359 [No Abstract] [Full Text] [Related]
53. Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry'. Mulhearn B Ann Rheum Dis; 2023 May; 82(5):e115. PubMed ID: 33648958 [No Abstract] [Full Text] [Related]
54. No higher risk of respiratory symptoms in Italian rheumatological patients under IL-6R-inhibitor therapy in SARS-CoV-2 pandemic. Alivernini S; Petricca L; Perniola S; Fedele AL; Gigante MR; Capacci A; Paglionico A; Varriano V; De Lorenzis E; Lanzo L; Melpignano F; Rubortone P; Tanti G; Tur C; Bruno D; Gigante L; Natalello G; Verardi L; Di Mario C; Tolusso B; Mirone L; Lizzio MM; Zoli A; Peluso G; Bosello SL; Gremese E Rheumatology (Oxford); 2020 Sep; 59(9):2644-2646. PubMed ID: 32728733 [No Abstract] [Full Text] [Related]
55. Your help is needed in the fight against COVID-19: Please contribute to the COVID-19 Global rheumatology alliance registry. Int J Rheum Dis; 2021 Nov; 24(11):1442. PubMed ID: 34724598 [No Abstract] [Full Text] [Related]
56. Response to 'To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic' by Parperis. Spinelli FR; Ceccarelli F; Di Franco M; Conti F Ann Rheum Dis; 2021 Jan; 80(1):e9. PubMed ID: 32366521 [No Abstract] [Full Text] [Related]
57. Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies. Sanchez-Piedra C; Diaz-Torne C; Manero J; Pego-Reigosa JM; Rúa-Figueroa Í; Gonzalez-Gay MA; Gomez-Reino J; Alvaro-Gracia JM; Ann Rheum Dis; 2020 Jul; 79(7):988-990. PubMed ID: 32503857 [No Abstract] [Full Text] [Related]
58. SARS-CoV-2 infection among patients with systemic autoimmune diseases. Emmi G; Bettiol A; Mattioli I; Silvestri E; Di Scala G; Urban ML; Vaglio A; Prisco D Autoimmun Rev; 2020 Jul; 19(7):102575. PubMed ID: 32376395 [TBL] [Abstract][Full Text] [Related]
59. Rheumatology research in the post-COVID era-challenges and solutions. Misra DP; Ravindran V Rheumatology (Oxford); 2023 Feb; 62(2):489-491. PubMed ID: 35792824 [No Abstract] [Full Text] [Related]